texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Waco Clinical Trials

Texas Oncology cancer centers in Waco participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Waco area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Waco area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Waco area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Waco area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Waco

Phase: II

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Breast Cancer

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Cervical Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Waco

Phase: II

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: II

Gastric Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Waco

Phase: II

Head and Neck Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: II

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Horizon Circle

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Waco

Phase: IV

Lung Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III/IV

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Lymphomas

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: I/II

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: II

Mesothelioma

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Waco

Phase: II

Myelofibrosis

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Waco

Phase: II

Neuroendocrine Tumors

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Waco

Phase: II

Other

Title: A Multicenter, Multicountry, Postmarketing Active Surveillance Taliglucerase Alfa Registry in Patients with Gaucher Disease (TALIAS) View

Indication: Other

Location: Texas Oncology-Waco

Penile Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Waco

Phase: II

Prostate Cancer

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: III

Rectal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Waco

Phase: II

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Waco

Phase: I/II

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Waco

Phase: II

Solid Tumors

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Waco

Phase: II

Testicular Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Waco

Phase: II

Thymomas

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Waco

Phase: II

Thyroid Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Waco

Phase: II

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Uterine Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Waco

Phase: II

Vaginal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Waco

Phase: II

Texas Oncology-Horizon Circle

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Horizon Circle

Phase: IV

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III/IV

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Texas Oncology-Waco

Title: A Multicenter, Multicountry, Postmarketing Active Surveillance Taliglucerase Alfa Registry in Patients with Gaucher Disease (TALIAS) View

Indication: Other

Location: Texas Oncology-Waco

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Waco

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Waco

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: II

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Waco

Phase: IV

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III/IV

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Waco

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Waco

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Waco

Phase: II

No Phase

Title: A Multicenter, Multicountry, Postmarketing Active Surveillance Taliglucerase Alfa Registry in Patients with Gaucher Disease (TALIAS) View

Indication: Other

Location: Texas Oncology-Waco

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Waco

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: I/II

Phase II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Waco

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Horizon Circle

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Waco

Phase: II

Phase III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waco

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Horizon Circle

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Waco

Phase: III

Phase III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Horizon Circle

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Waco

Phase: III/IV

Phase IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Horizon Circle

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Waco

Phase: IV